OneSource Specialty Pharma Limited has announced that its Board of Directors has decided not to proceed with the proposed Composite Scheme of Arrangement for the acquisition of SteriScience facilities in Poland and Baroda. Initially disclosed on February 26, 2026, the board has opted to shelve the current transaction in favor of prioritizing the successful delivery of the respective companies’ FY28 guidance before revisiting the integration strategy.
Strategic Decision on Acquisition
Following a deliberate review during the meeting held on May 13, 2026, the Board of Directors of OneSource Specialty Pharma Limited concluded that the proposed acquisition of SteriScience (Poland and Baroda) facilities will not be pursued in its current form. The decision reflects the company’s commitment to prioritizing the operational performance of all stakeholders involved.
Focus on Future Performance
The company has indicated that it intends to revisit the potential transaction only after achieving the successful delivery of the companies’ FY28 guidance. By shifting the focus toward meeting these core financial and operational objectives, management aims to ensure a more stable foundation for any future expansion or consolidation efforts. This pause allows the organization to consolidate its current internal performance before undertaking complex structural realignments.
Next Steps
While the initial in-principle approval was granted on February 26, 2026, the current update effectively halts the integration process for the time being. Investors and stakeholders should anticipate further updates once the designated financial performance benchmarks for FY28 are met, at which point the board will reassess the viability of the proposed merger and arrangement.
Source: BSE
